Analiza zmian w układzie immunologicznym podczas procesu starzenia się i onkogenezy psów

• Autorzy: Kempisty B. , Zawierucha P. , Zaorska K. , Dorszewska J. , Bukowska D. , Jaskowski J. M. , Nowicki M. , Zabel M.

Warianty tytułu

EN

Analysis of changes in the immunological system during canine senescence and oncogenesis

• Języki publikacji: PL

Abstrakty

EN

Senescence of the organism is a consequence of several molecular (induction of proapoptotic genes expression, DNA damage) and biochemical changes, which gradually leads to the degeneration of some systems and organs. One of the most important features of progressive senescence is also a decreased response of the immunological system (proinflammatory response), which may result in a higher susceptibility to infection. The process of oncogenesis is closely associated with the age of an animal and progressive senescence. However, the proper assessment of the association between the induction of oncogenesis and senescence is problematic, mainly with regards to several species specific features like the weight of a dog or its breed. Moreover, the association between the activity of the immunological system and oncogenesis in a dog in an age-dependent manner is also unclear. Studies have suggested that the main factors which influence the process of senescence and oncogenesis are: DNA damage, spontaneous mutations, increase of oxidative stress and decrease of immunological system activity. In this article, the mechanisms and factors associated with oncogenesis and canine senescence have been presented. The authors have also described the role of selected proteins in the induction of these processes.

Słowa kluczowe

PL

psy; starzenie sie; proces starzenia; onkogeneza; uklad odpornosciowy; przemiany biochemiczne; stres oksydacyjny

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2011
• Tom: 67
• Numer: 09
• Opis fizyczny: s.594-598,bibliogr.

Twórcy

autor

Kempisty B.

• Katedra i Zakład Histologii i Embriologii, Wydział Lekarski II, Uniwersytet Medyczny w Poznaniu, ul.Święcickiego 6, 60-781 Poznań

autor

Zawierucha P.

autor

Zaorska K.

autor

Dorszewska J.

autor

Bukowska D.

autor

Jaskowski J. M.

autor

Nowicki M.

autor

Zabel M.

Bibliografia

• 1.Allavena P., Sica A., Solinas G., Porta C., Mantovani A.: The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev. Oncol. Hematol. 2008, 66, 1-9.
• 2.Banks K. L.: Changes in the immune response related to age. Symposium on Internal Medicine and the Geriatric Patient. Veterinary Clinic of North America, Small Animal Practice 1981, 11, 683-688.
• 3.Caruso C., Magrone T., Jirillo E.: Low grade inflammation as a common pathogenetic denominator in age-related diseases: novel drug targets for anti-ageing strategies and successful ageing achievement. Curr. Pharm. Des. 2010, 16, 753.
• 4.Chen L. W., Chang W. J., Chen P. H., Liu W. C., Hsu C. M.: TLR ligand decreases mesenteric ischemia and reperfusion injury-induced gut damage through TNF-alpha signaling. Shock 2008, 30, 563-570.
• 5.Coussens L. M.: Werb Z. Inflammation and cancer. Nature 2002, 420, 860-867.
• 6.Culig Z., Steiner H., Bartsch G., Hobisch A.: Interleukin-6 regulation of prostate cancer cell growth. J. Cell. Biochem. 2005, 95, 497-505.
• 7.Dorszewska J., Adamczewska-Goncerzewicz Z., Szczech J.: Apoptotic proteins in the course of aging of central nervous system in the rat. Respir. Physiol. Neurobiol. 2004, 139, 145-155.
• 8.Dorszewska J., Florczak J., Rózycka A., Jaroszewska-Kolecka J., Trzeciak W. H., Kozubski W.: Polymorphisms of the CHRNA4 gene encoding the alpha4 subunit of nicotinic acetylcholine receptor as related to the oxidative DNA damage and the level of apoptotic proteins in lymphocytes of the patients with Alzheimer's disease. DNA Cell Biol. 2005, 24, 786-794.
• 9.Dorszewska J., Florczak J., Różycka A., Kempisty B., Jaroszewska-Kolecka J., Chojnacka K., Trzeciak W. H., Kozubski W.: Oxidative DNA damage and level of thiols as related to polymorphisms of MTHRF, MTR, MTHRD1 in Alzheimrs's and Parkinson's diseases. Acta Neurobiol. Exp. (Wars) 2007, 67, 113-129.
• 10.Dorszewska J., Kempisty B., Jaroszewska-Kolecka J., Rózycka A., Florczak J., Lianeri M., Jagodziński P. P., Kozubski W.: Expression and polymorphisms of gene 8-oxoguanine glycosylase 1 and the level of oxidative DNA damage in peripheral blood lymphocytes of patients with Alzheimer's disease. DNA Cell Biol. 2009, 28, 579-588.
• 11.Dummer W., Becker J. C., Schwaaf A., Leverkus M., Moll T., Bröcker E. B.: Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res. 1995, 5, 67-68.
• 12.Edwards J., Mukherjee R., Munro A. F., Wells A. C., Almushatat A., Bartlett J. M.: Her2 and COX expression in human prostate cancer. Eur. J. Cancer 2004, 40, 50-55.
• 13.Ershler W. B., Keller E. T.: Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu. Rev. Med. 2000, 51, 245-270.
• 14.Gocek E., Studzinski G. P.: Vitamin D and differentiation in cancer. Crit. Rev. Clin. Lab. Sci. 2009, 46, 190-209.
• 15.Goldston R. T., Hoskins J. D.: Geriatrics and Gerontology of the Dog and Cat. 1995.
• 16.Hayek M. G.: Age-related changes in physiological function in the dog and cat: nutritional implication. Recent Advances in Canine and Feline Nutrition. IAMS Nutrition Symposium Proceedings 1998, 2, 353-362.
• 17.Hayek M. G., Massimino S. P., Burr J. R., Kearns R. J.: Dietary vitamin E improves immune function in cats. Recent Advances in Canine and Feline Nutrition. IAMS Nutrition Symposium Proceedings 2000, 3, 555-563.
• 18.Heikkila K., Ebrahim S., Lawlor D. A.: Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur. J. Cancer. 2008, 44, 937-945.
• 19.Heinrich P. C., Behrmann I., Haan S., Hermanns H. M., Müller-Newen G., Schaper F.: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374, 1-20.
• 20.Hutchins D., Steel C. M.: Regulation of ICAM-1 (CD54) expression in human breast cancer cell lines by interleukin 6 and fibroblast-derived factors. Int. J. Cancer. 1994, 58, 80-84.
• 21.Kamimura D., Ishihara K., Hirano T.: IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev. Physiol. Biochem. Pharmacol. 2003, 149, 1-38.
• 22.Kearns R. J., Loos K. M., Chew B. P., Massimino S., Burr J. R., Hayek M. G.: The effect of age and dietary beta-carotene on immunological Parameters in the dog. Recent Advances in Canine and Feline Nutrition. IAMS Nutrition Symposium Proceedings 2000, 3, 389-401.
• 23.Mantovani A., Romero P., Palucka A. K., Marincola F. M.: Tumor immunity: effector response to tumor and role of the microenvironment. Lancet 2008, 371, 771-783.
• 24.Mocellin S., Nitti D.: TNF and cancer: the two sides of the coin. Front Biosci. 2008, 13, 2774-2783.
• 25.Salazar-Onfray F., López M. N., Mendoza-Naranjo A.: Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev. 2007, 18, 171-182.
• 26.Serafini M.: Dietary vitamin E and T cell-mediated function in the elderly: effectiveness and mechanism od action. International Journal of Developemental Neuroscience 2000, 18, 401-410.
• 27.Shacter E., Weitzman S. A.: Chronic inflammation and cancer. Oncology (Williston Park) 2002, 16, 217-226, 229; discussion 230-232.
• 28.Sheffy B. E., Williams A. J.: Nutrition and the aging animal. Veterinary Clinics of North America, Small Animal Practice 1981, 11, 669-675.
• 29.Sica A., Allavena P., Mantovani A.: Cancer related inflammation: the macrophage connection. Cancer Lett. 2008, 267, 204-215.
• 30.Smith W. I., Dewitt D. I., Garavito R. M.: Cyclooxygenases: structural, cellular and molecular biology. Annu. Rev. Biochem. 2006, 69, 145-182.
• 31.Stearns M. E., Rhim J., Wang M.: Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res. 1999, 5, 189-196.
• 32.Sun S., Rao N. L., Venable J., Thurmond R., Karlsson L.: TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007, 6, 223-235.
• 33.Szlosarek P. W., Balkwill F. R.: Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol. 2003, 4, 565-573.
• 34.Williams R. O.: Paradoxical effects of tumour necrosis factor-alpha in adjuvant-induced arthritis. Arthritis Res. Ther. 2008, 10, 113.
• 35.Wu W. K., Sung J. J., Lee C. W., Yu J., Cho C. H.: Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. Cancer Lett. 2010, 295, 7-16.